Key result
Sublingual nifedipine reduced pulmonary and systemic vascular resistance by 54% and 49% and increased cardiac output by 90.3% in a patient with severe primary pulmonary hypertension.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
The results of the medical treatment of primary pulmonary hypertension are usually very poor. A case of severe primary pulmonary hypertension in chronic heart failure was treated with the calcium antagonist nifedipine, a powerful vasodilator which acts directly on vascular smooth muscle. Nifedipine, administered in a dose of 20 mg sublingually, caused a pronounced fall in pulmonary and systemic vascular resistances (54 and 49%, respectively) and a rise in cardiac output (90.3%). Improvement was maintained over a three-month period. These data suggest that nifedipine can be used in the treatment of this condition.
No takes yet. Share an insight, caveat, or question.
Camerini et al. (1980) conducted a case report in severe primary pulmonary hypertension in chronic heart failure (n=1). Nifedipine was evaluated on pulmonary vascular resistance, systemic vascular resistance, and cardiac output. Sublingual nifedipine reduced pulmonary and systemic vascular resistance by 54% and 49% and increased cardiac output by 90.3% in a patient with severe primary pulmonary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: